Physician profile
Hammad Mohsin
NPI 1205167624
$7,054.88
in general payments reported to CMS, 2019-2025
21 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.44 · 2020: $123 · 2021: $121 · 2022: $351 · 2023: $981 · 2024: $3,940 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,656 · Travel and Lodging: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,656.21 |
| Travel and Lodging | $787.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,594.54 | 2024 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,343.22 | 2022-2025 | Caplyta |
| Alkermes, INC. | $1,061.16 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $692.23 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $498.84 | 2023-2025 | Auvelity |
| Abbvie INC. | $485.36 | 2023-2025 | |
| Bausch Health US, LLC | $249.50 | 2023-2024 | Aplenzin |
| Lundbeck LLC | $170.12 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Indivior INC. | $169.97 | 2023-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $145.87 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $125.46 | 2024 | Fanapt |
| Corium, LLC | $108.50 | 2024-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $107.73 | 2023-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $65.08 | 2024-2025 | Spravato |
| Almatica Pharma LLC | $51.69 | 2024-2025 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $39.09 | 2024 | |
| Neos Therapeutics, Lp | $38.26 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| E.R. Squibb & Sons, L.L.C. | $34.17 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $33.92 | 2025 | Qelbree |
| Braeburn INC. | $23.73 | 2024 | Brixadi |
| Acorda Therapeutics, INC | $16.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Mohsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.